Tech Company Financing Transactions
Oligomerix Funding Round
Private investors and Wheatley Partners participated in a $2.8 million Series B funding round for Oligomerix. The round was announced on 6/30/2013.
Transaction Overview
Company Name
Announced On
6/30/2013
Transaction Type
Venture Equity
Amount
$2,800,000
Round
Series B
Investors
Proceeds Purpose
Funding from the Series B round will allow Oligomerix to rapidly advance its drug discovery programs targeting tau protein oligomers that have recently been shown to be neurotoxic, impair memory formation and cause disease progression in disease models.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1300 Morris Park Ave. 1211
Bronx, NY 10461
USA
Bronx, NY 10461
USA
Phone
Website
Email Address
Overview
OLIGOMERIX Inc., is a biopharmaceutical company focused on developing novel drug discovery targets and therapeutics for Alzheimer's disease and other neurodegenerative disorders. Founded in 2006, OLIGOMERIX has filed patents on tau protein oligomers (soluble aggregates) for drug and biomarker discovery.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
James Moe
Chief Financial Officer
Robert Foerster
Chief Medical Officer
William Erhardt
Chief Scientific Officer
Eliot Davidowitz
VP - Marketing
Jack Pasini
Browse more venture capital transactions:
Prev: 6/30/2013: Sight Machine venture capital transaction
Next: 6/30/2013: Ocular Therapeutix venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs